These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

196 related items for PubMed ID: 31368635

  • 1. Initiation of droxidopa during hospital admission for management of refractory neurogenic orthostatic hypotension in severely ill patients.
    McDonell KE, Preheim BA, Diedrich A, Muldowney JAS, Peltier AC, Robertson D, Biaggioni I, Shibao CA.
    J Clin Hypertens (Greenwich); 2019 Sep; 21(9):1308-1314. PubMed ID: 31368635
    [Abstract] [Full Text] [Related]

  • 2. L-threo-dihydroxyphenylserine (L-threo-DOPS; droxidopa) in the management of neurogenic orthostatic hypotension: a multi-national, multi-center, dose-ranging study in multiple system atrophy and pure autonomic failure.
    Mathias CJ, Senard JM, Braune S, Watson L, Aragishi A, Keeling JE, Taylor MD.
    Clin Auton Res; 2001 Aug; 11(4):235-42. PubMed ID: 11710796
    [Abstract] [Full Text] [Related]

  • 3. Neurogenic orthostatic hypotension in Parkinson's disease: evaluation, management, and emerging role of droxidopa.
    Isaacson SH, Skettini J.
    Vasc Health Risk Manag; 2014 Aug; 10():169-76. PubMed ID: 24729712
    [Abstract] [Full Text] [Related]

  • 4. Safety and Durability of Effect with Long-Term, Open-Label Droxidopa Treatment in Patients with Symptomatic Neurogenic Orthostatic Hypotension (NOH303).
    Isaacson S, Shill HA, Vernino S, Ziemann A, Rowse GJ.
    J Parkinsons Dis; 2016 Oct 19; 6(4):751-759. PubMed ID: 27636856
    [Abstract] [Full Text] [Related]

  • 5. Droxidopa as an effective treatment for refractory neurogenic orthostatic hypotension and reflex bradycardia in amyloid light-chain amyloidosis: a case report.
    Ho AH, Kinter CW, Wight J, Neelam AR, Krakow D.
    J Med Case Rep; 2020 Jun 20; 14(1):73. PubMed ID: 32560740
    [Abstract] [Full Text] [Related]

  • 6. Droxidopa for neurogenic orthostatic hypotension: a randomized, placebo-controlled, phase 3 trial.
    Kaufmann H, Freeman R, Biaggioni I, Low P, Pedder S, Hewitt LA, Mauney J, Feirtag M, Mathias CJ, NOH301 Investigators.
    Neurology; 2014 Jul 22; 83(4):328-35. PubMed ID: 24944260
    [Abstract] [Full Text] [Related]

  • 7. Dysautonomia: A Forgotten Condition - Part 1.
    Rocha EA, Mehta N, Távora-Mehta MZP, Roncari CF, Cidrão AAL, Elias Neto J.
    Arq Bras Cardiol; 2021 Apr 22; 116(4):814-835. PubMed ID: 33886735
    [Abstract] [Full Text] [Related]

  • 8. Integrated analysis of droxidopa trials for neurogenic orthostatic hypotension.
    Biaggioni I, Arthur Hewitt L, Rowse GJ, Kaufmann H.
    BMC Neurol; 2017 May 12; 17(1):90. PubMed ID: 28494751
    [Abstract] [Full Text] [Related]

  • 9. Standing and Supine Blood Pressure Outcomes Associated With Droxidopa and Midodrine in Patients With Neurogenic Orthostatic Hypotension: A Bayesian Meta-analysis and Mixed Treatment Comparison of Randomized Trials.
    Chen JJ, Han Y, Tang J, Portillo I, Hauser RA, Dashtipour K.
    Ann Pharmacother; 2018 Dec 12; 52(12):1182-1194. PubMed ID: 29972032
    [Abstract] [Full Text] [Related]

  • 10. Supine plasma NE predicts the pressor response to droxidopa in neurogenic orthostatic hypotension.
    Palma JA, Norcliffe-Kaufmann L, Martinez J, Kaufmann H.
    Neurology; 2018 Oct 16; 91(16):e1539-e1544. PubMed ID: 30232253
    [Abstract] [Full Text] [Related]

  • 11. Analysis of number needed to treat for droxidopa in patients with symptomatic neurogenic orthostatic hypotension.
    François C, Rowse GJ, Hewitt LA, Vo P, Hauser RA.
    BMC Neurol; 2016 Aug 18; 16(1):143. PubMed ID: 27538531
    [Abstract] [Full Text] [Related]

  • 12. Managing supine hypertension in a patient with non-diabetic autonomic neuropathy receiving droxidopa for neurogenic orthostatic hypotension.
    Vernino S, Lew M, Kremens D.
    Clin Auton Res; 2017 Jul 18; 27(Suppl 1):35-37. PubMed ID: 28623420
    [No Abstract] [Full Text] [Related]

  • 13. Droxidopa for the short-term treatment of symptomatic neurogenic orthostatic hypotension in Parkinson's disease (nOH306B).
    Hauser RA, Isaacson S, Lisk JP, Hewitt LA, Rowse G.
    Mov Disord; 2015 Apr 15; 30(5):646-54. PubMed ID: 25487613
    [Abstract] [Full Text] [Related]

  • 14. Randomized withdrawal study of patients with symptomatic neurogenic orthostatic hypotension responsive to droxidopa.
    Biaggioni I, Freeman R, Mathias CJ, Low P, Hewitt LA, Kaufmann H, Droxidopa 302 Investigators.
    Hypertension; 2015 Jan 15; 65(1):101-7. PubMed ID: 25350981
    [Abstract] [Full Text] [Related]

  • 15. Cognitive and Behavioral Changes in Patients Treated With Droxidopa for Neurogenic Orthostatic Hypotension: A Retrospective Review.
    McDonell KE, Shibao CA, Biaggioni I, Hartman A, Robertson D, Claassen DO.
    Cogn Behav Neurol; 2019 Sep 15; 32(3):179-184. PubMed ID: 31517701
    [Abstract] [Full Text] [Related]

  • 16. Cardiovascular Safety of Droxidopa in Patients With Symptomatic Neurogenic Orthostatic Hypotension.
    White WB, Hauser RA, Rowse GJ, Ziemann A, Hewitt LA.
    Am J Cardiol; 2017 Apr 01; 119(7):1111-1115. PubMed ID: 28159196
    [Abstract] [Full Text] [Related]

  • 17. Droxidopa: a review of its use in symptomatic neurogenic orthostatic hypotension.
    Keating GM.
    Drugs; 2015 Feb 01; 75(2):197-206. PubMed ID: 25559422
    [Abstract] [Full Text] [Related]

  • 18. Norepinephrine precursor therapy in neurogenic orthostatic hypotension.
    Kaufmann H, Saadia D, Voustianiouk A, Goldstein DS, Holmes C, Yahr MD, Nardin R, Freeman R.
    Circulation; 2003 Aug 12; 108(6):724-8. PubMed ID: 12885750
    [Abstract] [Full Text] [Related]

  • 19. Long-term safety of droxidopa in patients with symptomatic neurogenic orthostatic hypotension.
    Isaacson S, Vernino S, Ziemann A, Rowse GJ, Kalu U, White WB.
    J Am Soc Hypertens; 2016 Oct 12; 10(10):755-762. PubMed ID: 27614923
    [Abstract] [Full Text] [Related]

  • 20. Cost-effectiveness of droxidopa in patients with neurogenic orthostatic hypotension: post-hoc economic analysis of Phase 3 clinical trial data.
    François C, Hauser RA, Aballéa S, Dorey J, Kharitonova E, Hewitt LA.
    J Med Econ; 2016 Oct 12; 19(5):515-25. PubMed ID: 26710315
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.